Why the study?
Heart failure with preserved ejection fraction remains a clinical challenge due to its heterogeneous presentation and limited therapeutic options, making accurate phenotyping essential for diagnosis and personalized treatment.
Key points are not available for this paper at this time.
Design
Review
No immediate change to HFpEF care warranted; leaves open need for prospective validation of ML phenotyping.
Heart failure with preserved ejection fraction (HFpEF) remains a major clinical challenge due to its heterogeneous presentation and limited therapeutic options. Accurate patient phenotyping is essential to improve diagnosis, prognostication, and treatment personalization. Machine learning (ML) has emerged as a powerful tool to identify clinically meaningful HFpEF subgroups by integrating diverse data sources, including clinical, imaging, biomarker, and physiological parameters. ML-based models can uncover subtle patterns not captured by traditional methods, offering improved risk stratification, earlier intervention, and guidance toward individualized therapy. Future progress will rely on standardized data collection, validation across populations, and incorporation into clinical decision support systems. Advancements in explainable artificial intelligence, federated learning, and multi-omics integration are expected to further refine phenotyping strategies and translate into improved patient outcomes. Continued interdisciplinary collaboration is essential to unlock the full potential of ML in transforming HFpEF management.
No takes yet. Share an insight, caveat, or question.
Potoupni et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: